National Institutes of Health logo
NIH Phase 1 Exploratory/Developmental Cooperative Agreement (UG3)

Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose

Funds discovering and developing a medication or device to prevent or treat substance use disorders and overdose, in two phases.

A treatment for substance use disorder or overdose has to clear the same distance as any other drug or device — discovery, then evidence it works — and this notice funds both legs as one award.

What counts is broad on purpose: medications and medical devices, aimed at preventing or treating substance use disorders and overdose, including the disorders that commonly ride alongside them.

The mecha

Discovery and development of medications and medical devices to prevent or treat substance use disorders and overdose, including co-occurring disorders, through a phased cooperative agreement moving preclinical and clinical candidates toward regulatory approval or clinical adoption.

CycleiHow often this grant runs — e.g. annually, on a rolling basis, or a one-off call.Multiple per year
Next deadlineiThe next date applications are due. Rolling means you can apply any time.21 Aug 2028
Decision timeiTypical time from the deadline to the funder's decision.26 weeks
Project durationiHow long the funded work is expected to run.
Award typeiThe form of funding — grant, equity, loan, tax credit, etc.Cooperative agreement
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.
Funding pooliThe total budget available across all awards in this round.

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Sign up free to see how to apply

Sign up free to see what you submit

Sign up free to see how they score you

Sign up free to see the timeline

Sign up free to see where teams trip up

Last verified: 25 Aug 2026Funder reference: PAR-25-446Source: www.grants.gov